Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pramlintide acetate Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Amylin and Glucagon in T1DM

NCT00206258
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide and glucagon
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

NCT06422325
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system in insulin only mode, MPC closed-loop system in insulin/pramlintide mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

NCT00673387
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, metreleptin, placebo-P, placebo-M
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 4 Interventional Results available

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

NCT01269047
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Exenatide, Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00189514
View directory record Official record
Conditions
Obesity
Interventions
pramlintide acetate, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
21
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 4 Interventional

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT00950677
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Byetta (exenatide), Symlin (pramlintide)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

NCT00313183
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

NCT00819234
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Pramlintide and Metreleptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

NCT00206297
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 3 Interventional

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

NCT00042458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pramlintide acetate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Terminated Not applicable Interventional

Pramlintide Combined With Model Predictive Control Algorithm

NCT01434862
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 26, 2026, 12:42 AM EDT
Terminated Not applicable Interventional Results available

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-PORT, standard injections
Device · Other
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 4 Interventional

Continuous Subcutaneous Infusion of Pramlintide and Insulin

NCT00291772
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 22 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

NCT01708044
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide acetate, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 26, 2026, 12:42 AM EDT